Filing Details
- Accession Number:
- 0000950170-24-062585
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-20 18:30:26
- Reporting Period:
- 2024-05-20
- Accepted Time:
- 2024-05-20 18:30:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1422143 | Kura Oncology Inc. | KURA | Pharmaceutical Preparations (2834) | 611547851 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1813058 | Brophy Teresa Bair | C/O Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego CA 92130 | Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-05-20 | 2,615 | $22.15 | 68,979 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023.
- 2615 shares were acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.
- This transaction was executed in multiple trades at prices ranging from $22.06 to $22.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The reported sale of 2,615 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023.